Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Share-based Compensation (2022 - 2025)

Historic Share-based Compensation for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $7.2 million.

  • Centessa Pharmaceuticals' Share-based Compensation fell 1489.41% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.4 million, marking a year-over-year decrease of 396.35%. This contributed to the annual value of $33.5 million for FY2024, which is 1413.31% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Share-based Compensation of $7.2 million as of Q3 2025, which was down 1489.41% from $7.9 million recorded in Q2 2025.
  • Centessa Pharmaceuticals' Share-based Compensation's 5-year high stood at $8.6 million during Q2 2024, with a 5-year trough of $5.6 million in Q2 2022.
  • In the last 4 years, Centessa Pharmaceuticals' Share-based Compensation had a median value of $7.4 million in 2023 and averaged $7.4 million.
  • As far as peak fluctuations go, Centessa Pharmaceuticals' Share-based Compensation surged by 2873.46% in 2023, and later tumbled by 1489.41% in 2025.
  • Over the past 4 years, Centessa Pharmaceuticals' Share-based Compensation (Quarter) stood at $6.6 million in 2022, then rose by 12.29% to $7.4 million in 2023, then increased by 12.09% to $8.3 million in 2024, then dropped by 13.62% to $7.2 million in 2025.
  • Its Share-based Compensation was $7.2 million in Q3 2025, compared to $7.9 million in Q2 2025 and $7.9 million in Q1 2025.